Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts.
Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts. Cancer Res. 2008 Sep 15; 68(18):7493-501.